Case of capecitabine‑induced dermatomyositis (Record no. 8621)

MARC details
000 -LEADER
fixed length control field a
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20190514115934.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190324b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency AIKTC-KRRC
Transcribing agency AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN) 8218
Author Saraswat, Neerja
245 ## - TITLE STATEMENT
Title Case of capecitabine‑induced dermatomyositis
250 ## - EDITION STATEMENT
Volume, Issue number Vol. 50(6), November-December
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Mumbai
Name of publisher, distributor, etc. Wolter Kluwer
Year 2018
300 ## - PHYSICAL DESCRIPTION
Pagination 350-353p.
520 ## - SUMMARY, ETC.
Summary, etc. Dermatomyositis (DM) is an idiopathic, inflammatory connective tissue disorder characterized by symmetrical proximal myopathy and characteristic skin involvement. The pathogenesis of DM is widely debated; however, it is postulated to be an end result of immune‑mediated cascade, triggered by multiple environmental factors in a genetically predisposed individual. In addition to underlying malignancies, many drugs have been reported to be associated with DM. Capecitabine is a chemotherapeutic agent, approved by the United States‑Food and Drug Administration for the management of colonic, metastatic colonic, and metastatic breast carcinoma. It is converted into 5‑fluorouracil after oral intake. Common dose‑limiting toxicities associated with the usage of the capecitabine include increased bilirubin levels, diarrhea, and hand‑foot syndrome. DM‑induced by capecitabine has rarely been reported. Herein, we describe a patient of metastatic carcinoma breast, who developed DM after capecitabine intake. The patient had accidental re‑challenge with capecitabine resulting in the reappearance of the cutaneous and musculoskeletal system, thereby confirming our diagnosis of drug‑induced DM in the setting of underlying malignancy.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4774
Topical term or geographic name entry element PHARMACOLOGY
653 ## - Keywords
Keywords Breast carcinoma
653 ## - Keywords
Keywords Capecitabine
653 ## - Keywords
Keywords Dermatomyositis
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 8219
Co-Author Verma, Rajesh
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 8220
Co-Author Shekha, Neema
773 0# - HOST ITEM ENTRY
Place, publisher, and date of publication Andheri - Mumbai Wolters Kluwer India Private Limited
International Standard Serial Number 0253-7613
Title Indian Journal of Pharmacology
856 ## - ELECTRONIC LOCATION AND ACCESS
URL http://www.ijp-online.com/temp/IndianJPharmacol506350-1488709_040807.pdf
Link text Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Articles Abstract Database
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     School of Pharmacy School of Pharmacy Archieval Section 29/03/2019   2018289 19/06/2019 29/03/2019 Articles Abstract Database
Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.